^
4d
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
P1, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
IMSA101
1m
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
P2, N=51, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
1m
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
P2, N=6, Terminated, ImmuneSensor Therapeutics Inc. | N=46 --> 6 | Trial completion date: Feb 2026 --> Sep 2024 | Recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Sep 2024; Slow enrollment.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
2ms
New P2 trial • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • IMSA101
6ms
The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. (PubMed, Nat Commun)
Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.
Journal • CAR T-Cell Therapy
|
STING (stimulator of interferon response cGAMP interactor 1) • IL18 (Interleukin 18)
|
IL18 elevation
|
IMSA101
1year
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial (clinicaltrials.gov)
P1/2, N=2, Active, not recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
IMSA101
1year
Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
P1/2, N=40, Completed, ImmuneSensor Therapeutics Inc. | Recruiting --> Completed | N=115 --> 40 | Trial completion date: Dec 2023 --> Sep 2023
Trial completion • Enrollment change • Trial completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
HR negative
|
IMSA101
over1year
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies (clinicaltrials.gov)
P2, N=51, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
over1year
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC (clinicaltrials.gov)
P2, N=46, Recruiting, ImmuneSensor Therapeutics Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
over1year
New P2 trial • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
over1year
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101
over1year
Safety and Efficacy Study of IMSA101 in Refractory Malignancies (clinicaltrials.gov)
P1/2, N=115, Recruiting, ImmuneSensor Therapeutics Inc. | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Oct 2023
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
HR negative
|
IMSA101